[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[@onco_park](/creator/twitter/onco_park)
"Q224_Genmab's Oncology X. Genmab's R&D strategy will focus on advancing mid-to-late-stage projects like EPKINLY Tivdak acasunlimab and Rina-S. While early-stage investments have reached a satisfactory level future efforts will be more moderate prioritizing pivotal trials and potential registrations for key assets. X. At #ESMO24 updated data on Rina-S will be presented showing significant activity across various FR expression levels compared to Elehere. Genmab plans to initiate a Phase X trial for 2L PROC by the end of 2024. The company attributes Rina-S's superior safety profile to its"  
[X Link](https://x.com/onco_park/status/1821951433668735007) [@onco_park](/creator/x/onco_park) 2024-08-09T16:47Z 2361 followers, 1960 engagements


"Ono Pharmaceutical has inked two key deals with LigaChem Biosciences. First Ono secured worldwide exclusive rights to LCB97 LCB's L1CAM-targeting ADC for solid tumors. Second the companies agreed to collaborate on developing new ADC candidates using LCB's ConjuAll ADC platform"  
[X Link](https://x.com/onco_park/status/1844304885627453842) [@onco_park](/creator/x/onco_park) 2024-10-10T09:12Z 2361 followers, XXX engagements


"J&J has decided not to exercise its license option for HexaBody-CD38. Genmab will discontinue further clinical development of HexaBody-CD38 maintaining its previously stated focus on advancing late-stage assets Rina-S and acasunlimab. HexaBody-CD38 showed slightly higher ORR VGPR and CR rates compared to daratumumab though the differences were not substantial"  
[X Link](https://x.com/onco_park/status/1899107328022188100) [@onco_park](/creator/x/onco_park) 2025-03-10T14:37Z 2361 followers, 4105 engagements